| Autor: |
Homayoon Khanlou, Robert Corales, Frank Rhame, Daniel J. Skiest, Thanes Vanig, Karam Mounzer, Nicholaos C. Bellos, Edwin DeJesus, Calvin J. Cohen, Hannah Olivet, Andrew E. Petroll, Marc Tribble, Jane Garb |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
HIV & AIDS Review. 11:77-83 |
| ISSN: |
1730-1270 |
| DOI: |
10.1016/j.hivar.2012.10.001 |
| Popis: |
Objectives To determine if switching virologically suppressed patients on a regimen containing lopinavir/r (LPV/r) or fosamprenavir (FPV/r) to darunavir/r (DRV/r) or atazanavir/r (ATV/r) results in improved TGs while maintaining virological suppression. Methods Eligibility criteria were undetectable HIV RNA ≥12 weeks, no PI resistance, receiving LPV/r ( n = 46) or FPV/r ( n = 3) plus nucleosides, and fasting TGs >200 mg/dl. Patients were randomized to either QD ATV/r or DRV/r (maintaining the same nucleosides). Primary endpoint was change in TGs from baseline to week 24. Results 66 were screened, 51 enrolled and two withdrew consent after randomization. 24 patients received ATV/r; 25 received DRV/r. Baseline mean CD4 cell count was 569; HIV RNA was p Conclusions Patients with high TGs who switched from LPV/r or FPV/r to DRV/r or ATV/r had improved TGs, while maintaining virological suppression and high adherence and QOL. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
